Patents by Inventor Ramses Ayala

Ramses Ayala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1 Peptide Inhibitors
    Publication number: 20240075131
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 7, 2024
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20230414703
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Application
    Filed: June 1, 2023
    Publication date: December 28, 2023
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 peptide inhibitors
    Patent number: 11793856
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Grant
    Filed: September 9, 2020
    Date of Patent: October 24, 2023
    Assignee: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20210000948
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20200405803
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Application
    Filed: September 9, 2020
    Publication date: December 31, 2020
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 peptide inhibitors
    Patent number: 10799581
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: October 13, 2020
    Assignee: Leidos, inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 peptide inhibitors
    Patent number: 10799555
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: October 13, 2020
    Assignee: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Patent number: 10098950
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 16, 2018
    Assignee: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20180200328
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 19, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20180185474
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20180071385
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Application
    Filed: September 15, 2017
    Publication date: March 15, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala